David Azad is a principal with Galen Partners. Prior to joining Galen in 2006, he was an associate principal in the health care practices of McKinsey & Company. He began his career as an attorney with Latham & Watkins in Washington, DC, where he focused on health care and tax law.
In addition to serving on the Board of Directors for Nautilus, Mr. Azad serves on the board of Unisyn Medical Technologies and is also a board observer for Acura Pharmaceuticals.
John Groom retired in 2001 as president and chief operating officer of Elan. Prior to assuming that role in 1997, he was president, chief executive officer, and a director of Athena Neurosciences for nearly 10 years. He was earlier employed by Smith Kline and French Laboratories, a division of the company that is now GlaxoSmithKline. He has served on the Board of Directors of Elan, Amarin, Ligand Pharmaceuticals, and CV Therapeutics, and has helped found various other start-ups. He is a fellow of the Association of Certified Accountants (UK).
Chief Executive Officer
William Maichle has more than 15 years of experience in drug development, mergers and acquisitions, licensing, sales and marketing, and pharmaceutical operations. His career includes senior management positions at PharmaNet, Otsuka, and Kowa Pharmaceuticals America (formerly ProEthic Pharmaceuticals).
Frank V. Sica
Frank Sica has been a managing partner at Tailwind Capital since 2005. Previously, he was president of Soros Private Funds Management and a managing director at Morgan Stanley and its private equity affiliate, Morgan Stanley Capital Partners.
He has served as an officer in the US Air Force and has served on the Board of Directors of Safe Bulkers, CSG Systems International, JetBlue Airways, and Kohl’s Department Stores.
Geoffrey S. Raker
Geoffrey Raker is a managing director at Tailwind Capital. Prior to joining Tailwind in 2003 he was a vice president at Warburg Pincus in their healthcare group. Mr. Raker joined Warburg Pincus from Morgan Stanley, where he was a vice president in mergers & acquisitions. He started his career as a consultant with Bain & Company. Mr. Raker currently serves on the Board of Directors of Trover Solutions and VersaPharm, and previously served on the Boards of Aircast Incorporated and ChartOne, Inc.
Peter A. Lankau,
Executive Chairman of the Board
Mr. Lankau is an experienced biopharmaceutical executive with nearly 30 years of general management expertise in developing and commercializing pharmaceutical products. As the former CEO of Logical Therapeutics, Inc., a development stage biopharmaceutical company, he led the company in its development of NSAIDs for the chronic treatment of inflammatory disease and now serves on their Board of Directors.
Prior to Logical, Mr. Lankau was the former President and Chief Executive Officer, and member of the Board of Directors, of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company where he led the company in developing its pipeline in the pain management and supportive oncology therapeutic areas, including more than 12 product acquisitions/licenses. His previous position was VP Sales and Marketing at Alpharma and he began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis, Inc.) in multiple commercial roles, and was most recently Vice President, Sales-US Pharmaceuticals.
Zubeen Shroff is a managing director of Galen Partners, a leading health care growth equity investment firm. Prior to joining Galen in 1997, he was a principal at The Wilkerson Group, a leading medical products management consulting firm.
Mr. Shroff started his career at Schering-Plough Pharmaceuticals, where he directed the marketing, sales, and phase 4 clinical development activities for the company’s biotech business in France.
Mr. Shroff serves on the boards of several Galen portfolio companies and the Westchester Medical Center. He is also chairman of the medical center’s foundation. In addition, Mr. Shroff is a member of the Dean’s Advisory Committee for Boston University Medical School.